“Step-down” therapy for asthma: Why, when, and how?
Author:
- Leonard B. BacharierLBLeonard B. Bacharier
- 1 June 2002
- journal article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 109 (6) , 916-919
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Eosinophil markers in blood, serum, and urine for monitoring the clinical course in childhood asthma: Impact of budesonide treatment and withdrawalJournal of Allergy and Clinical Immunology, 2001
- Long-Term Effects of Budesonide or Nedocromil in Children with AsthmaNew England Journal of Medicine, 2000
- Treatment of Allergic Asthma with Monoclonal Anti-IgE AntibodyNew England Journal of Medicine, 1999
- The long‐acting β2‐agonist salmeterol xinafoate: effects on airway inflammation in asthmaEuropean Respiratory Journal, 1999
- Does salmeterol facilitate “step-down” therapy in patients with asthma receiving moderate to high doses of inhaled corticosteriods?Current Therapeutic Research, 1998
- Potential Masking Effects of Salmeterol on Airway Inflammation in AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 1998
- A Comparison of Low-Dose Inhaled Budesonide plus Theophylline and High-Dose Inhaled Budesonide for Moderate AsthmaNew England Journal of Medicine, 1997
- Effects of Reducing or Discontinuing Inhaled Budesonide in Patients with Mild AsthmaNew England Journal of Medicine, 1994
- Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroidThe Lancet, 1994
- Reduction of budesonide after a year of increased use: A randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintainedJournal of Allergy and Clinical Immunology, 1991